9th Nov 2011 07:00
9 November 2011
Cyprotex PLC
Cyprotex Improves Predictive Technology for Pharmacokinetics
Major Upgrade to Cloe® PK Pharmacokinetic Model
Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today announces major enhancements to Cloe® PK, Cyprotex's pharmacokinetic prediction software.
Cloe® PK™ enables scientists in the drug discovery and agrochemical industries to use ADME and physicochemical data to predict human and rodent pharmacokinetics (process by which a drug is absorbed, distributed, metabolised, and eliminated by the body). These predictions allow prospective compounds to be ranked and prioritised for success potential prior to or even without the need for expensive and time-consuming in vivo studies. Cloe® PK has already been shown to predict aspects of human pharmacokinetics better than extrapolation from animal in vivo studies.
Twenty-seven key parameters are used to measure Cloe® PK's performance. The enhancements to Cloe® PK have improved accuracy on 16 of these 27 parameters. These parameters summarise the model's capability to predict aspects of human and rodent pharmacokinetics, including clearance, distribution, half-life, and oral absorption.
Several of the enhancements were facilitated through collaboration with one of Cyprotex's major clients who provided Cyprotex with a large in vivo dataset for building and testing the improvements to the model.
Cloe® PK is available either as a site license, or on an as-needed basis via Cyprotex's online portal, Cloe® Gateway (www.cloegateway.com).
Cyprotex's Chief Scientific Officer, Dr Katya Tsaioun, comments: "Cyprotex is the only ADME Tox contract research organisation with in-house expertise in both in vitro and in silico ADME and has a unique capacity to help clients understand the relationship between in vitro data, in silico predictions, and in vivo performance*. Cyprotex continues to refine the Cloe® PK software and this latest enhancement increases the model's reliability and usability. Cloe® PK speeds up the process of selecting compound candidates to create a drug and it reduces the need for expensive and time-consuming animal pharmacokinetic studies."
* in vitro - in tube; in silico - computer generated; and in vivo - in animal
For more information, see http://www.cyprotex.com/cloepredict/physiological_modelling/cloe-pk/ .
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | ir@cyprotex.com www.cyprotex.com |
Singer Capital Markets Limited (broker to Cyprotex) | Tel: +44 (0) 203 205 7500 |
Shaun Dobson Claes Spang
| shaun.dobson@singercm.com claes.spang@singercm.com www.singercm.com |
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Ben Brewerton Ben Atwell Mo Noonan | cyprotex@fticonsulting.com www.fticonsulting.com
|
Notes to Editors:
Cyprotex PLC
Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.
Related Shares:
CRX.L